How Long Do Sulfur Burps Last with Mounjaro? Mapping the Tirzepatide Weekly Cycle

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 10 sources cited

Key Takeaways

• Mounjaro is once-weekly tirzepatide. Plasma concentrations peak roughly 24 to 48 hours after injection, and sulfur-burp intensity tracks that curve.
• An individual sulfur-burp episode on Mounjaro typically lasts 12 to 36 hours after a triggering meal. Healthy stomach equivalent: 2 to 6 hours.
• The weekly susceptibility window centers on days 1 to 3 after injection. Days 5 to 7 are typically the lowest-burden days for most patients.
• Each dose increase produces a 2 to 4 week peak in symptoms, easing over the following 4 to 8 weeks as the body adapts
• After stopping, gastric emptying returns to baseline within 1 to 3 weeks and sulfur burps usually resolve in the same window

Direct answer

On Mounjaro, a single sulfur-burp episode usually lasts 12 to 36 hours. The worst day-of-week timing is 24 to 48 hours after injection, when tirzepatide plasma levels peak and gastric emptying is most slowed. The overall susceptibility persists throughout active therapy and resolves 1 to 3 weeks after stopping the medication.

Table of contents

1. Mounjaro pharmacokinetics: why timing matters
2. The episode duration on tirzepatide
3. The weekly oscillation
4. How dose level changes the picture
5. The adaptation curve at each new dose
6. The maintenance plateau
7. What happens after stopping
8. Mounjaro versus Zepbound: same drug, similar timing
9. Mounjaro versus Ozempic: comparing weekly cycles
10. When duration on Mounjaro becomes a red flag
11. FAQ
12. Sources

Mounjaro pharmacokinetics: why timing matters

Tirzepatide is a once-weekly subcutaneous injection. Per Eli Lilly's prescribing information and pharmacokinetic studies, time to peak plasma concentration (Tmax) is approximately 24 to 48 hours after injection. Steady-state plasma levels are reached after about 4 weeks at any given dose.

The drug acts on both GIP and GLP-1 receptors. Both systems contribute to slowed gastric emptying. The slowing effect is most pronounced when plasma concentrations are highest, which is the day after and the day after that.

This shapes the sulfur-burp timeline because the burps are produced by hydrogen sulfide gas accumulating in a stomach that is emptying too slowly. More gastric slowing means more time for sulfur-rich foods to ferment, means more gas, means more burps.

The episode duration on tirzepatide

A single high-sulfur meal in a normal stomach produces sulfur burps for roughly 2 to 6 hours. The same meal on Mounjaro produces burps for roughly 12 to 36 hours.

Why the extension? Gastric emptying half-time approximately doubles on GLP-1 receptor agonists. Tirzepatide adds GIP receptor effects on top, which may extend the slowing further at peak plasma levels.

Practical implication: a sulfur-rich dinner eaten the night before injection can produce burps lasting into the next day. A sulfur-rich dinner eaten the night after injection (during peak plasma levels) can produce burps lasting through to the following evening.

The weekly oscillation

Once-weekly Mounjaro produces a predictable rise-and-fall in plasma concentration. Side effects, including sulfur burps, oscillate with that pattern.

Day after injection	Plasma level (relative)	Typical sulfur-burp intensity
Day 0 (injection day)	Rising	Mild to moderate
Day 1	Near peak	Moderate to high
Day 2	Peak	Highest weekly burden for most patients
Day 3	Declining from peak	Moderate
Day 4	Mid-declining	Mild to moderate
Day 5 to Day 7	Trough levels	Lowest weekly burden, often the "good days"

Patients who keep a symptom diary for 2 to 3 weeks usually identify their personal peak window and can plan meals around it. Heavy protein meals scheduled for days 5 to 7, lighter meals on days 1 to 3, is a common adjustment.

How dose level changes the picture

Mounjaro doses range from 2.5 mg (starting) to 15 mg (highest). The pharmacokinetic principles are consistent across doses, but the magnitude of gastric slowing scales with plasma concentration.

Dose	Typical sulfur-burp prevalence	Notes
2.5 mg	Uncommon	Starting dose, mainly for tolerability
5 mg	Occasional	First dose with meaningful weight-loss effect
7.5 mg	Moderate	Often the first dose with persistent symptoms
10 mg	Common	Many patients adapt within 4 to 8 weeks
12.5 mg	Common	Symptoms typically more pronounced
15 mg	Common	Highest peak plasma levels, longest episode durations

These prevalence categories come from patient communities and clinical observation, not formal trial data. The SURMOUNT-1 trial reported eructation and dyspepsia rates without separating sulfur-specific burps from general belching.

The adaptation curve at each new dose

Each dose increase triggers a temporary spike in side effects. The pattern across patients:

• Weeks 1 to 2 of new dose: Sulfur burps may intensify or appear for the first time
• Weeks 3 to 4: Peak intensity for many patients
• Weeks 5 to 8: Gradual reduction as the body adapts
• Weeks 9 and beyond: Plateau at a new stable level, usually better than the peak but rarely back to pre-dose-increase baseline

If symptoms are severe in weeks 1 to 4 of a new dose, options to discuss with the prescriber include:

• Staying at the previous dose for another 4 weeks before re-attempting the increase
• Holding the current new dose for 8 weeks rather than 4 before further escalation
• Targeted dietary changes and bismuth subsalicylate for symptomatic relief

The maintenance plateau

Patients at a stable maintenance dose (typically 5, 10, or 15 mg depending on response and tolerability) settle into a steady-state symptom pattern. From clinical observation:

• Roughly one-third report sulfur burps becoming rare and easy to manage
• Roughly one-third report intermittent flares tied to specific foods or weeks
• Roughly one-third report persistent weekly susceptibility throughout therapy

The plateau is not a guarantee of permanent stability. Holidays, travel, illness, and food choices can trigger flares even after months of relative quiet.

What happens after stopping

Tirzepatide has a half-life of approximately 5 days. Five half-lives is about 25 days for full elimination, but the gastric slowing effect typically wanes faster because receptor activation is concentration-dependent.

Typical post-stop timeline:

• Week 1: Sulfur burps still common, especially mid-week (when the last injection would have peaked)
• Week 2: Substantial reduction as plasma levels fall below the threshold for major gastric slowing
• Week 3: Most patients report return to pre-treatment GI baseline
• Week 4 and beyond: Persistent sulfur burps beyond this point are unusual and warrant evaluation for other causes (food intolerance, gastroparesis from another cause, infection)

Mounjaro versus Zepbound: same drug, similar timing

Mounjaro and Zepbound are both tirzepatide. Same molecule, same pharmacokinetics. The brand difference reflects FDA-approved indication (Mounjaro: type 2 diabetes; Zepbound: obesity) rather than any difference in drug behavior.

Sulfur-burp timing, duration, and pattern are identical between the two. Patient reports converge on the same weekly cycle and adaptation curve. If you switch from Mounjaro to Zepbound or vice versa at the same dose, expect no change in sulfur-burp behavior.

Mounjaro versus Ozempic: comparing weekly cycles

Ozempic is semaglutide, with a half-life of about 7 days. Mounjaro is tirzepatide, half-life about 5 days. Both are once-weekly.

Practical differences for sulfur-burp timing:

• Semaglutide peak plasma concentration: roughly 1 to 3 days after injection
• Tirzepatide peak plasma concentration: roughly 1 to 2 days after injection
• Both produce a 2 to 4 day peak symptom window, followed by gradual decline

Patients switching between drugs report similar overall symptom burden, with some noting that tirzepatide's slightly faster peak produces a more concentrated "bad days" cluster early in the week, while semaglutide's longer half-life produces a flatter, more drawn-out curve.

When duration on Mounjaro becomes a red flag

Most episodes resolve within the windows described. Escalate to your prescriber when:

• A single episode persists more than 36 hours despite dietary management
• Episodes recur daily despite injection day and food adjustments
• Vomiting accompanies the burps for more than 24 hours
• Food eaten hours earlier comes back up undigested
• Severe abdominal pain develops
• Unintentional weight loss exceeds expected trajectory substantially

The FDA updated GLP-1 receptor agonist labels in 2023 to reflect postmarketing reports of gastroparesis. The condition is uncommon but real. Persistent sulfur burps combined with the above symptoms warrant evaluation.

The contrary view: weekly timing may matter less than total exposure

Patients often focus on the weekly cycle. There is a reasonable counterview: total weekly exposure to tirzepatide, integrated across all 7 days, may matter more than the peak.

Plasma concentration during the trough days (5 to 7) is still meaningfully above zero. Gastric emptying is still slowed compared to baseline. A patient who eats sulfur-rich meals on "good days" still has higher residual susceptibility than someone not on the drug at all.

This is why most patients report some level of sulfur-burp susceptibility throughout the week, not just on peak days. The weekly cycle modulates intensity, not the underlying mechanism.

FAQ

How long do sulfur burps last with Mounjaro? Individual episodes: 12 to 36 hours. Weekly cycle: worst days 1 to 3 after injection. Overall susceptibility: throughout active therapy.

When are sulfur burps worst on Mounjaro? Roughly 24 to 48 hours after injection, when tirzepatide plasma levels peak.

Does Mounjaro cause sulfur burps more than Ozempic? Similar prevalence across patient reports. Tirzepatide may produce slightly more intense GI symptoms at peak doses due to dual receptor effects, but direct comparison data is limited.

Do sulfur burps go away with dose adaptation on Mounjaro? Often partially. Most patients adapt over 4 to 8 weeks at each dose, with peak intensity in weeks 1 to 4.

How long do sulfur burps last after stopping Mounjaro? Typically 1 to 3 weeks. Tirzepatide half-life is about 5 days.

Why are sulfur burps worse on certain days? Plasma tirzepatide peaks 24 to 48 hours after injection. Gastric slowing tracks that curve.

Do sulfur burps last longer on higher Mounjaro doses? Yes, modestly. Higher doses produce more pronounced gastric slowing.

Should I change my injection day if sulfur burps are bad? Many patients find that injecting on a day when they can keep meals light (often Saturday for a weekend recovery window) reduces overall symptom burden.

Can I take Pepto-Bismol for sulfur burps on Mounjaro? Yes, intermittently. Bismuth subsalicylate binds hydrogen sulfide directly. Use as needed for breakthrough episodes, not daily long-term.

Will sulfur burps return if I increase my Mounjaro dose? Often yes, temporarily. Each dose increase produces a 2 to 4 week peak in symptoms before adaptation reduces frequency.

Are sulfur burps worse at 15 mg Mounjaro? Generally yes. The highest dose produces the most pronounced gastric slowing and the most consistent reports of persistent symptoms.

Related guides

• How Long Do Sulfur Burps Last? The Episode Versus the Syndrome
• How Long Does Tirzepatide Take to Suppress Appetite? Mapping the Food Noise Drop
• Sulfur Burps on Zepbound: Why Your Stomach Smells Like a Rotten Egg
• How to Get Rid of Sulfur Burps from Ozempic: The Treatment Playbook
• How Long Does Mounjaro Last in the Fridge? Refrigerator Storage and Validation
• How Long Does Tirzepatide Last in the Body? Three Phases of Drug Residence
• Tool: weight-loss timeline tool

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Eli Lilly. Mounjaro (tirzepatide) Prescribing Information. 2024.
4. Eli Lilly. Zepbound (tirzepatide) Prescribing Information. 2024.
5. Drucker DJ. Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism. 2018.
6. FDA. Drug Label Update: GLP-1 Receptor Agonists and Gastroparesis. 2023.
7. Aronne LJ et al. Continued Treatment With Tirzepatide: SURMOUNT-4. JAMA. 2024.
8. American College of Gastroenterology. Clinical Guideline: Gastroparesis. 2022.
9. Carbonero F et al. Hydrogen Sulfide Production in the Human Colon. Frontiers in Physiology. 2012.
10. Suarez FL et al. Bismuth Subsalicylate and Hydrogen Sulfide Release. Gastroenterology. 1998.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform connecting patients to licensed providers and U.S.-based pharmacies. We do not provide medical advice. Treatment plans, including responses to side effects on Mounjaro or any other medication, are determined by the prescribing clinician.

Compounded Medication Notice. Compounded tirzepatide is prepared by 503A pharmacies under individual prescriptions. It is not FDA-approved and is not therapeutically interchangeable with Mounjaro or Zepbound. Side-effect timing on compounded preparations may differ.

Results Disclaimer. Sulfur-burp duration, weekly timing, and adaptation patterns vary widely across patients. Population averages described here reflect clinical observation and patient-reported data and should not be applied to any individual without clinical judgment.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic is a registered trademark of Novo Nordisk A/S. Pepto-Bismol is a registered trademark of Procter and Gamble. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.